VIR-7831 (sotrovimab) + Placebo
Phase 2/3Completed 0 watching 0 views this week๐ Rising
60
Development Stage
โ
Pre-clinicalโ
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Covid19
Conditions
Covid19
Trial Timeline
Aug 27, 2020 โ Sep 2, 2021
NCT ID
NCT04545060About VIR-7831 (sotrovimab) + Placebo
VIR-7831 (sotrovimab) + Placebo is a phase 2/3 stage product being developed by Vir Biotechnology for Covid19. The current trial status is completed. This product is registered under clinical trial identifier NCT04545060. Target conditions include Covid19.
Hype Score Breakdown
Clinical
22
Activity
15
Company
5
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04545060 | Phase 2/3 | Completed |
Competing Products
20 competing products in Covid19